Mediolanum International Funds Ltd Takes Position in DaVita Inc. (NYSE:DVA)

Mediolanum International Funds Ltd purchased a new position in DaVita Inc. (NYSE:DVA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,811 shares of the company’s stock, valued at approximately $868,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC raised its stake in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA raised its position in shares of DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after buying an additional 108,446 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares in the last quarter. KBC Group NV boosted its position in shares of DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after acquiring an additional 67,250 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of DaVita during the third quarter worth $10,346,000. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

DVA has been the subject of a number of research reports. Truist Financial upped their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $161.80.

DaVita Price Performance

DaVita stock opened at $176.16 on Monday. The company has a market cap of $14.44 billion, a price-to-earnings ratio of 19.00, a PEG ratio of 0.85 and a beta of 0.92. The firm’s fifty day moving average is $159.72 and its 200 day moving average is $155.28. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 52-week low of $107.74 and a 52-week high of $179.60.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.